阿替普酶治疗急性脑梗死的疗效和安全性研究

摘要

Objective To study the effect and safety of alteplase on acute cerebral infarction. Methods 36 patients with acute cerebral infarction were treated with alteplase from January 2011 to March 2012. Results After 6 h of thrombolytic therapy,the NIHSS decreased obviously ( 16. 75 ±4. 56 vs. 23. 89 ± 6. 17 ,P < 0. 05 ),and there was significant difference in NIHSS between the 6th and 24th hour ( 10. 78 ± 3. 72 vs. 16. 75 ±4. 56, P < 0. 05 ) as well as 24th hour and 7th day ( 5. 47 ± 1. 96 vs. 10. 78 ±3. 72,P <0. 05 ). Conclusion Intravenous thrombolytic therapy of alteplase is a safe and effective treatment for acute cerebral infarction within a certain therapeutic time window.%目的 评价阿替普酶治疗急性脑梗死的疗效和安全性.方法 2011年1月-2012年3月收治的急性脑梗死患者共36例,给予阿替普酶溶栓治疗.结果 溶栓后6 h,患者NIHSS较溶栓前明显降低(16.75±4.56 vs.23.89±6.17,P<0.05),24 h NIHSS较溶栓后6 h明显降低(10.78±3.72 vs.16.75±4.56,P<0.05),7 d NIHSS较24 h明显降低(5.47±1.96 vs.10.78±3.72,P<0.05).结论 在一定的时间窗内,阿替普酶治疗急性脑梗死安全有效.